Literature DB >> 27566619

Clinical Applications of Dexamethasone for Aged Eyes.

Beatriz Abadia1, Pilar Calvo2,3, Antonio Ferreras1,4, Fran Bartol1, Guayente Verdes5, Luis Pablo1,4.   

Abstract

The risk of severe eye problems has been found to increase significantly with age, particularly between the fifth and sixth decades of life. Cataracts, dry eye, neovascular age-related macular degeneration, diabetic retinopathy and retinal vein occlusion (RVO) are very common and very different age-related ocular diseases that reduce the patient's quality of life. The rationale for using corticosteroids to treat anterior and posterior ocular segment diseases is driven by inflammation. Dexamethasone, one of the most powerful corticosteroids available, is widely used for topical or intravitreal administration. Topical dexamethasone has proven efficacy for the management of postoperative inflammation in the anterior segment after cataract surgery and symptom relief in dry-eye disease. A new sustained-release 700 µg dexamethasone intravitreal implant (DEX) was recently approved for the treatment of macular edema following RVO, diabetic macular edema, or non-infectious uveitis, and its use is increasing, especially when other therapeutic agents have failed. The most common side effects are increased intraocular pressure and cataract formation. The potency of DEX, alone or in combination with other agents, makes DEX a promising option for treating several retinal diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27566619     DOI: 10.1007/s40266-016-0392-z

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  64 in total

1.  Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial.

Authors:  E Albrecht; J C Richards; T Pollock; C Cook; L Myers
Journal:  Br J Ophthalmol       Date:  2011-02-02       Impact factor: 4.638

2.  Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.

Authors:  David M Brown; Peter A Campochiaro; Robert B Bhisitkul; Allen C Ho; Sarah Gray; Namrata Saroj; Anthony P Adamis; Roman G Rubio; Wendy Yee Murahashi
Journal:  Ophthalmology       Date:  2011-08       Impact factor: 12.079

Review 3.  Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye.

Authors:  Thorsteinn Loftsson; Einar Stefánsson
Journal:  Acta Ophthalmol Scand       Date:  2002-04

4.  Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone.

Authors:  Albert J Augustin; Stephan Puls; Indre Offermann
Journal:  Retina       Date:  2007-02       Impact factor: 4.256

5.  Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial.

Authors:  Baruch D Kuppermann; Michaella Goldstein; Raj K Maturi; Ayala Pollack; Michael Singer; Adnan Tufail; Dov Weinberger; Xiao-Yan Li; Ching-Chi Liu; Jean Lou; Scott M Whitcup
Journal:  Ophthalmologica       Date:  2015-06-18       Impact factor: 3.250

6.  Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency.

Authors:  Javier Zarranz-Ventura; Ester Carreño; Robert L Johnston; Quresh Mohammed; Adam H Ross; Carl Barker; Alex Fonollosa; Joseba Artaraz; Laura Pelegrin; Alfredo Adan; Richard W Lee; Andrew D Dick; Ahmed Sallam
Journal:  Am J Ophthalmol       Date:  2014-09-08       Impact factor: 5.258

7.  Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection.

Authors:  H W Kwak; D J D'Amico
Journal:  Arch Ophthalmol       Date:  1992-02

8.  Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.

Authors:  W Lloyd Clark; David S Boyer; Jeffrey S Heier; David M Brown; Julia A Haller; Robert Vitti; Husain Kazmi; Alyson J Berliner; Kristine Erickson; Karen W Chu; Yuhwen Soo; Yenchieh Cheng; Peter A Campochiaro
Journal:  Ophthalmology       Date:  2015-10-30       Impact factor: 12.079

9.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Authors:  Jeffrey S Heier; David M Brown; Victor Chong; Jean-Francois Korobelnik; Peter K Kaiser; Quan Dong Nguyen; Bernd Kirchhof; Allen Ho; Yuichiro Ogura; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Yuhwen Soo; Majid Anderesi; Georg Groetzbach; Bernd Sommerauer; Rupert Sandbrink; Christian Simader; Ursula Schmidt-Erfurth
Journal:  Ophthalmology       Date:  2012-10-17       Impact factor: 12.079

10.  Twelve-Month Results of a Single or Multiple Dexamethasone Intravitreal Implant for Macular Edema following Uncomplicated Phacoemulsification.

Authors:  Solmaz Abdolrahimzadeh; Vito Fenicia; Maurizio Maurizi Enrici; Pasquale Plateroti; Dora Cianfrone; Santi Maria Recupero
Journal:  Biomed Res Int       Date:  2015-10-05       Impact factor: 3.411

View more
  9 in total

1.  Results from the Population-Based Gutenberg Health Study Revealing Four Altered Autoantibodies in Retinal Vein Occlusion Patients.

Authors:  Katharina Bell; Vanessa M Beutgen; Stefan Nickels; Katrin Lorenz; Yvonne Scheller; Hisham Elbaz; Tunde Peto; Katharina A Ponto; Andreas Schulz; Philipp S Wild; Thomas Münzel; Karl J Lackner; Irene Schmidtmann; Manfred Beutel; Norbert Pfeiffer; Franz H Grus; Alexander K Schuster
Journal:  J Ophthalmol       Date:  2020-07-29       Impact factor: 1.909

2.  Manufacturing of Dexamethasone-Poly(d,l-Lactide-co-Glycolide) Implants Using Hot-Melt Extrusion: Within- and Between-Batch Product Performance Comparisons.

Authors:  Ryan A Kelley; Alireza Ghaffari; Yan Wang; Stephanie Choi; Jonathan R Taylor; Rachel R Hartman; Uday B Kompella
Journal:  J Ocul Pharmacol Ther       Date:  2020-04-24       Impact factor: 2.671

3.  Dexamethasone distribution characteristic following controllable continuous sub-tenon drug delivery in rabbit.

Authors:  Xuetao Huang; Manqiang Peng; Yezhen Yang; Yiqin Duan; Kuanshu Li; Shaogang Liu; Changhua Ye; Ding Lin
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 4.  Intracameral dexamethasone injection in the treatment of cataract surgery induced inflammation: design, development, and place in therapy.

Authors:  Tirth J Shah; Mandi D Conway; Gholam A Peyman
Journal:  Clin Ophthalmol       Date:  2018-11-01

5.  Effects of preoperative doses of betamethasone acetate 0.1% on dry eye control after cataract surgery.

Authors:  Saeed Shokoohi-Rad; Seyedeh Zeinab Hashemi Javaheri; Fatemeh Zare Malekabad; Hamid Khakshoor; Mohammad Khajeh Daluee
Journal:  Indian J Ophthalmol       Date:  2020-03       Impact factor: 1.848

Review 6.  A One-Week Course of Levofloxacin/Dexamethasone Eye Drops: A Review on a New Approach in Managing Patients After Cataract Surgery.

Authors:  Stanislao Rizzo; Gloria Gambini; Umberto De Vico; Clara Rizzo; Raphael Kilian
Journal:  Ophthalmol Ther       Date:  2021-12-22

Review 7.  Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems.

Authors:  Vijay Sagar Madamsetty; Reza Mohammadinejad; Ilona Uzieliene; Noushin Nabavi; Ali Dehshahri; Jomarien García-Couce; Shima Tavakol; Saeid Moghassemi; Arezoo Dadashzadeh; Pooyan Makvandi; Abbas Pardakhty; Abbas Aghaei Afshar; Ali Seyfoddin
Journal:  ACS Biomater Sci Eng       Date:  2022-04-19

8.  Cyclodextrin-containing hydrogels as an intraocular lens for sustained drug release.

Authors:  Xiao Li; Yang Zhao; Kaijie Wang; Lei Wang; Xiaohui Yang; Siquan Zhu
Journal:  PLoS One       Date:  2017-12-15       Impact factor: 3.240

9.  Pharmacokinetics of Pullulan-Dexamethasone Conjugates in Retinal Drug Delivery.

Authors:  Eva Kicková; Amir Sadeghi; Jooseppi Puranen; Shirin Tavakoli; Merve Sen; Veli-Pekka Ranta; Blanca Arango-Gonzalez; Sylvia Bolz; Marius Ueffing; Stefano Salmaso; Paolo Caliceti; Elisa Toropainen; Marika Ruponen; Arto Urtti
Journal:  Pharmaceutics       Date:  2021-12-21       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.